Regulatory Information
AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD
AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD
Therapeutic
Prescription Only
Formulation Information
INJECTION, SOLUTION
**2.2 Dosage and Administration** Adults (≥ 18 years): One 6 mg dose (a single pre-filled syringe) of pegfilgrastim is recommended for each chemotherapy cycle, administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy. Neulastim therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.
SUBCUTANEOUS
Medical Information
**2.1 Therapeutic Indication(s)** Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
**2.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 1.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
L03AA13
pegfilgrastim
Manufacturer Information
AMGEN BIOTECHNOLOGY SINGAPORE PTE. LTD.
Amgen Manufacturing, Limited
Active Ingredients
Documents
Package Inserts
Neulastim Injection PI.pdf
Approved: June 21, 2021